UK pharma major AstraZeneca (LSE: AZN) today announced that Sharon Barr has been appointed executive vice president, BioPharmaceuticals R&D.
Ms Barr will succeed Sir Mene Pangalos, who is retiring and will step down from his role early next year, after almost 14 yars with the company and an illustrious 35-year career.
Ms Barr will be responsible for discovery through to late-stage development across cardiovascular, renal and metabolism and respiratory and immunology. She will report to chief executive Sir Pascal Soriot and become a member of AstraZeneca’s senior executive team (SET) as of August 1.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze